Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia After Trial Longitudinal Assessment Study (PATH-HHT ATLAS)

NCT07018401 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07018401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia After Trial Longitudinal Assessment Study (PATH-HHT ATLAS)
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Completed
Start date
May 1, 2024
Completion date
June 1, 2026
Enrollment
62 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)